VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CPX-351 for high-risk AML

Thomas Cluzeau
EHA 2020
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, outlines therapies for poor-risk acute myeloid leukemia (AML), including CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Cluzeau

1:04
The future of MDS management
Thomas Cluzeau • 30 Sep 2020
4:54
AML treatment: ASH 2020 and beyond
Thomas Cluzeau • 9 Dec 2020
1:38
APR-246 and azacitidine in TP53m MDS and AML
Thomas Cluzeau • 7 Dec 2019
1:24
Phase II trial of eprenetapopt plus azacitidine: long-term follow up
Thomas Cluzeau • 13 Dec 2021

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals